Interleukin-6 and insulin incrase and nitric oxide and adiponectin decrease in blind dogs with pituitary-dependent hyperadrenocorticism

Research in Veterinary Science

Volumn 93, Issue 3, 2012, Pages 1195-1202

  Cabrera Blatter, M F ^a   del Prado, B ^a   Miceli, D D ^a   Gomez, N ^a   Ivanic, J ^a   Di Tollo, B ^a   Gallelli, M F ^a   Castillo, V A ^a  

^a HospitalEscuela de Medicina Veterinaria F Cs Veterinarias UBA   (Argentina)

Author keywords

Adiponectin; IL 6; Insulin; Nitric oxide; Pituitary dependent hypercortisolism

Indexed keywords

ADIPONECTIN; CORTICOTROPIN; CREATININE; GLUCOSE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; NITRIC OXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLINDNESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; FEMALE; HORMONE DETERMINATION; HYPERCORTISOLISM; HYPERTENSION; INSULIN SENSITIVITY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PITUITARY DEPENDENT HYPERCORTISOLISM;

ADIPONECTIN; ANIMALS; BLINDNESS; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION; INSULIN; INTERLEUKIN-6; NITRIC OXIDE; PITUITARY ACTH HYPERSECRETION;

CANIS FAMILIARIS;

EID: 84866843212     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2012.02.003     Document Type: Article

References (67)

1. Andrews R.C., Walker B.R. Glucocorticoids and insulin resistance. Old hormones, new targets. Clinical Science (London) 1999, 96:513-523.
2. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., Fava G.A., Findling J.W., Gaillard R.C., Grossman A.B., Kola B., Lacroix A., Mancini T., Mantero F., Newell-Price J., Nieman L.K., Sonino N., Vance M.L., Giustina A., Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003, 88:5593-5602.
3. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., Capeau J., Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European Cytokine Network 2006, 17:4-12.
4. Bhargava M., Ikram M.K., Wong T.Y.J. How does hypertension affect your eyes?. Human Hypertension 2011, 10.1038/jhh.2011.37.
5. Bodey A.R., Michell A.R. Epidemiological study of blood pressure in domestic dogs. Journal of Small Animal Practice 1996, 37:116-125.
6. Brochu-Gaudreau K., Rehfeldt C., Blouin R., Bordignon V., Murphy B.D., Palin M.F. Adiponectin action from head to toe. Endocrinology 2010, 37:11-32.
7. Brown S., Atkins C., Bagley R., Carr A., Cowgill L., Davidson M., Egner B., Elliott J., Henik R., Labato M., Littman M., Polzin D., Ross L., Snyder P., Stepien R. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine 2007, 21:542-558.
8. Cabrera Blatter M.F., del Prado A., Gallelli M.F., D'Anna E., Ivanic J., Esarte M., Miceli D.D., Gómez N.V., Castillo V.A. Blindness in dogs with pituitary dependent hyperadrenocorticism: relationship with glucose, cortisol and triglyceride concentration and with ophthalmic blood flow. Research in Veterinary Science 2011, 92:387-392.
9. Cartier A., Lemieux I., Alméras N., Tremblay A., Bergeron J., Després J.P. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor α in men. Journal of Clinical Endocrinology and Metabolism 2008, 93:1931-1938.
10. de Ferranti S., Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clinical Chemistry 2008, 54:945-955.
11. Dodson P.M., Galton D.J., Hamilton A.M., Blach R.K. Retinal vein occlusion and the prevalence of lipoprotein abnormalities. British Journal of Ophthalmology 1982, 66:161-164.
12. Duncan B.B., Schmidt M.I., Chambless L.E., Folsom A.R., Carpenter M., Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC study. Obesity Research 2000, 8:279-286.
13. Esteve E., Castro A., López Bermejo A., Vendrell J., Ricart W., Fernández Real J.M. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care 2007, 30:939-945.
14. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical Biophysical Research Communication 2003, 301:1045-1050.
15. Galac S., Kooistra H., Teske E., Rijnberk A. Urinary corticoid/creatinin ratio in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Veterinary Quarterly 1997, 19:17-20.
16. Gallelli M.F., Cabrera Blatter M.F., Castillo V. A comparative study by age and gender of the pituitary adenoma and ACTH and a-MSH secretion in dogs with pituitary-dependent hyperadrenocorticism. Research in Veterinary Science 2010, 88:33-40.
17. German A.J., Hervera M., Hunter L., Holden S.L., Morris P.J., Biourge V., Trayhurn P. Improvement in insulin resistance and reduction in plasma inflammatory adipokines after weight loss in obese dogs. Domestic Animal Endocrinology 2009, 37:214-226.
18. German A.J., Ryan V.H., German A.C., Wood S., Trayhurn P. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. The Veterinary Journal 2010, 185:4-9.
19. Haluzic M., Parizkova J., Haluzic M.M. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiology Research 2004, 53:123-129.
20. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Current Opinion Lipidology 2002, 13:51-59.
21. Hess R.S., Kass P.H., Van Winkle T.J. Association between diabetes mellitus, hypothyroidism or hyperadrenocorticism, and atherosclerosis in dogs. Journal of Veterinary Internal Medicine 2003, 17:489-494.
22. Hollwich F., Dieckhues B. Circadian rhythm in the blind. Biological Rhythm 1971, 2:291-301.
23. Irving R.J., Walker B.R., Noon J.P., Watt G.C., Webb D.J., Shore A.C. Microvascular correlates of blood pressure, plasma glucose and insulin resistance in health. Cardiovascular Research 2002, 53:271-276.
24. Ishioka K., Omachi A., Sagawa M., Shibata H., Honjoh T., Kimura K., Saito M. Canine adiponectin: cDNA structure, mRNA expression in adipose tissues and reduced plasma levels in obesity. Research in Veterinary Science 2006, 80:127-132.
25. Iwasaki Y., Takayasu S., Nishiyama M., Tsugita M., Taguchi T., Asai M., Yoshida M., Kambayashi M., Hashimoto K. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11-hydroxysteroid dehydrogenase type 1) gene. Molecular and Cellular Endocrinology 2008, 285:10-18.
26. Jones T.H. Interleukin-6 an endocrine cytokine. Clinical Endocrinology 1994, 40:703-713.
27. Kageyama K., Kagaya S., Takayasu S., Hanada K., Iwasaki Y., Suda T. Cytokines induce NF-κB, Nurr1 and corticotropin-releasing factor gene transcription in hypothalamic 4B cells. Neuroimmunomodulation 2010, 17:305-313.
28. Kato K., Osawa H., Ochi M., Kusunoki Y., Ebisui O., Ohno K., Ohashi J., Shimizu I., Fujii Y., Tanimoto M., Makino H. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clinical Endocrinology 2008, 68:442-449.
29. Kawano J., Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. Journal of the Cardio Metabolic Syndrome 2009, 4:44-49.
30. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004, 89:2548-2556.
31. Lien Y.H., Hsiang T.Y., Huang H.P. Associations among systemic blood pressure, microalbuminuria and albuminuria in dogs affected with pituitary- and adrenal-dependent hyperadrenocorticism. Acta Veterinaria Scandinavica 2010, 12:52-61.
32. Loscalzo J. Nitric oxide and vascular disease. New England Journal of Medicine 1995, 333:251-253.
33. Luchi T., Akaike M., Mitsui T., Ohshima Y., Shintani Y., Azuma H., Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circulation Research 2003, 92:81-87.
34. Matsuzawa Y., Funahashi T., Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. Journal of Atherosclerosis and Thrombosis 2011, 10.5551/jat.7922.
35. Matthew D., Davis M.D. Diabetic retinopathy: a clinical overview. Diabetes Care 1992, 15:1844-1874.
36. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
37. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and Cellular Endocrinology 2010, 314:1-16.
38. Meehan W.P., Darwin C.H., Maalouf N.B., Buchanan T.A., Saad M. Insulin and hypertension: are they related?. Steroids 1993, 58:621-634.
39. Miceli D.D., Gallelli M.F., Cabrera Blatter M.F., Martiarena B., Brañas M.M., Ortemberg L.R., Gomez N.V., Castillo V.A. Low dose of insulin detemir controls glycaemia, insulinemia and prevents diabetes mellitus progression in the dog with pituitary-dependent hyperadrenocorticism. Research in Veterinary Science 2011, 93:114-120.
40. Mitchell B.M., Webb R.C. Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biological Research for Nursing 2002, 4:16-21.
41. Morton N.M., Seckl J.R. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Frontiers of Hormone Research 2008, 36:146-164.
42. Nguyen T., Wong T.Y. Retinal vascular manifestations of metabolic disorders. Trends in Endocrinology and Metabolism 2006, 17:262-268.
43. Nichols R. Concurrent illness and complications associated with canine hyperadrenocorticism. Problems of Veterinary Medicine 1990, 2:565-572.
44. Ortega T.M., Feldman E.C., Nelson R.W. Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. Journal of American Veterinary Medical Association 1996, 209:172-1724.
45. Orth D.N., Besser G.M., King P.H., Nicholson W.E. Free-running circadian plasma cortisol rhythm in a blind human subject. Clinical Endocrinology 1978, 10:603-617.
46. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clinica Chimica Acta 2007, 380:24-30.
47. Paoletta A., Arnaldi G., Papa R., Boscaro M., Tirabassi G. Intrapituitary cytokines in Cushing's disease: do they play a role?. Pituitary 2011, 14:236-241.
48. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF α and IL-6. Diabetes Research and Clinical Practice 2005, 69:29-35.
49. Ridray S. Hyperinsulinemia and smooth muscle cells proliferation. Internal Journal of Obesity 1995, 19:S39-51.
50. Ross E.J., Linch D.C. Cushing's syndrome-killing disease: discriminatory values of signs and symptoms aiding early diagnosis. Lancet 1982, 2:646-649.
51. Sack R.L., Lewy A.J., Blood M.L., Keith L.D., Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. Journal of Clinical Endocrinology and Metabolism 1992, 75:127-134.
52. Shimada K., Miyazaki T., Daida H. Adiponectin and atherosclerotic disease. Clinical Chimical Acta 2004, 344:1-12.
53. Steinberg H.O., Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia 2002, 45:623-634.
54. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., Stewart P.M. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Review 2004, 25:831-866.
55. Tsagarakis S., Kontogeorgos G., Kovacs K. The role of cytokines in the normal and neoplastic pituitary. Critical Reviews in Oncology and Hematology 1998, 28:73-90.
56. Van Hecke M.V., Dekker J.M., Nijpels G., Moll A.C., Heine R.J., Bouter L.M., Polak B.C.P., Stehouwer C.D.A. Inflammation and endothelial dysfunction are associated with retinopathy: the hoorn study. Diabetologia 2005, 48:1300-1306.
57. Vegiopoulos A., Herzig S. Glucocorticoids, metabolism and metabolic diseases. Molecular and Cellular Endocrinology 2007, 275:43-61.
58. Verkest K.R., Fleeman L.M., Rand J.S., Morton J.M. Basal measures of insulin sensitivity and insulin secretion and simplified glucose tolerance tests in dogs. Domestic Animal Endocrinology 2010, 39:194-204.
59. Verkest K.R., Rand J.S., Fleeman L.M., Morton J.M., Richards A.A., Rose F.J., Whitehead J.P. Distinct adiponectin profiles might contribute to differences in susceptibility to type 2 diabetes in dogs and humans. Domestic Animal Endocrinology 2011, 41:67-73.
60. Vila E., Salaices M. Cytokines and vascular reactivity in resistance arteries. American Physiology-Heart Circulatory Physiology 2005, 288:1016-1021.
61. Wake D.J., Walker B.R. 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Molecular and Cellular Endocrinology 2004, 215:45-54.
62. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectinemia in obesity and Type 2 Diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 2001, 86:1930-1935.
63. Wong T.Y., Duncan B.B., Golden S., Klein R., Couper D., Klein B., Hubbard L., Sharrett A., Schmidt M. Associations between the metabolic syndrome and retinal microvascular signs: the atherosclerosis risk in communities study. Investigative Ophthalmology and Visual Science 2004, 45:2949-2954.
64. Wong T.Y., Mitchell P. The eye in hypertension. Lancet 2007, 369:425-435.
65. Yamauchi T., Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Internal Journal of Obesity 2008, 32:S13-S18.
66. Yang S., Zhang L. Glucocorticoids and vascular reactivity. Current Vascular Pharmacology 2004, 2:1-12.
67. Zarković M., Ignjatović S., Dajak M., Cirić J., Beleslin B., Savić S., Stojković M., Bulat P., Trbojević B. Cortisol response to ACTH stimulation correlates with blood interleukin 6 concentration in healthy humans. European Journal Endocrinology 2008, 159:649-652.